From: Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients
Site of portal vein thrombosis | n = 52 |  |
 MPV | 11 | 21% |
 MPV + intrahepatic branch | 17 | 32% |
 MPV + SMV | 6 | 11% |
 MPV + SMV + intrahepatic branch | 3 | 6% |
 MPV + SV | 2 | 4% |
 MPV + SV + intrahepatic branch | 2 | 4% |
 MPV + SMV + SV | 2 | 4% |
 MPV + SMV + SV + intrahepatic branch | 1 | 2% |
 SMV | 2 | 4% |
 SMV + intrahepatic branch | 1 | 2% |
 RPV | 2 | 4% |
 LPV | 2 | 4% |
 LPV + SV | 1 | 2% |
Degree of portal vein thrombosis | n = 52 |  |
 Partial obstruction | 46 | 89% |
 Complete obstruction | 6 | 11% |
Bauer’s Classification | n = 52 |  |
 Grade I | 0 | 0% |
 Grade II | 15 | 29% |
 Grade III | 26 | 50% |
 Grade IV | 11 | 21% |
Period from diagnosis to treatment | n = 52 |  |
  ≤ 30 days | 32 | 62% |
  > 31 days | 20 | 38% |
Period from last test not showing thrombosis to treatment | n = 52 |  |
  ≤ 90 days | 14 | 27% |
 91–180 | 12 | 23% |
  > 181 days | 14 | 27% |
 Undetermined | 12 | 23% |